Banquet, Sébastien <br/><br/>
Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure.  [electronic resource] 

 -  Circulation  Aug 2011 
 - 1059-69 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.110.010264  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inducing Agents--administration & dosage<br/>Animals<br/>Capsules<br/>Cardiomegaly--drug therapy<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Chronic Disease<br/>Coronary Vessels--drug effects<br/>Drug Therapy, Combination<br/>Fibroblast Growth Factor 2--administration & dosage<br/>Heart Failure--prevention & control<br/>Hepatocyte Growth Factor--administration & dosage<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mitogen-Activated Protein Kinases--metabolism<br/>Myocardium<br/>Neovascularization, Physiologic--drug effects<br/>Oncogene Protein v-akt--metabolism<br/>Rats<br/>Rats, Wistar